1.00
Silexion Therapeutics Corp stock is traded at $1.00, with a volume of 162.13K.
It is up +0.00% in the last 24 hours and up +0.81% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$1.00
Open:
$0.9898
24h Volume:
162.13K
Relative Volume:
0.02
Market Cap:
$8.12M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.0429
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
+7.03%
1M Performance:
+0.81%
6M Performance:
-54.09%
1Y Performance:
+0.00%
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLXN
Silexion Therapeutics Corp
|
1.00 | 8.12M | 0 | -16.42M | -6.75M | -23.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News
Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -
Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa
SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks
Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia
Silexion Therapeutics enters collaboration with Catalent - TipRanks
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World
Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com
Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire
Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Expands SIL204 Development Plan - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com
Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener
Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan
Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World
Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN
Silexion announces completion of expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire
Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Corp SEC 10-K Report - TradingView
Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan
Silexion Therapeutics reaches deal to retire convertible note - Investing.com
Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks
Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal
Silexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer - Benzinga
Silexion Therapeutics Reports Positive Data for SIL204 - TipRanks
Silexion reports initial data from systemic administration of SIL204 - TipRanks
Silexion Therapeutics Reports Positive Efficacy Data for SIL204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - StreetInsider.com
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - GlobeNewswire
Can Silexion's New Pancreatic Cancer Drug Stop Metastasis? Early Data Shows 80% Tumor Reduction - StockTitan
Can Silexion's RNAi Therapy Revolutionize Pancreatic Cancer Treatment? March Data Will Tell - StockTitan
Is Now The Time To Buy Silexion Therapeutics Corp (NASDAQ: SLXN) Stock? - Stocks Register
Silexion completes study of SIL-204 in orthotopic pancreatic cancer models - BioWorld Online
Silexion completes initial study of SIL-204 in pancreatic cancer models - TipRanks
Silexion Therapeutics Completes Initial Study of SIL-204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics Announces Completion of Initial Study - GlobeNewswire
Can Silexion's RNA Therapy Change Pancreatic Cancer Treatment? Key Study Completed - StockTitan
Comparing Silexion Therapeutics (NASDAQ:SLXN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):